C - Chemistry – Metallurgy – 12 – P
Patent
C - Chemistry, Metallurgy
12
P
C12P 21/08 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01)
Patent
CA 2053206
The present invention provides a human monoclonal antibody against melanoma, characterised in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunisation, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalised, antibodies from the immortalised B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.
Albert Winfried
Brandt Michael
Endl Josef
Jungfer Herbert
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
Roche Diagnostics Gmbh
LandOfFree
Monoclonal antibodies against melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against melanoma will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1677820